USANA Health Sciences (USNA) to Release Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is expected to be releasing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $225.9590 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 11:00 AM ET.

USANA Health Sciences Price Performance

Shares of NYSE USNA opened at $21.12 on Tuesday. The stock’s 50-day moving average is $20.58 and its two-hundred day moving average is $24.03. USANA Health Sciences has a 1-year low of $18.48 and a 1-year high of $38.32. The company has a market cap of $385.98 million, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 0.91 and a beta of 0.67.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Zacks Research cut shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, USANA Health Sciences has an average rating of “Reduce” and a consensus price target of $36.00.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of USNA. Two Sigma Investments LP grew its holdings in shares of USANA Health Sciences by 349.8% during the third quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock worth $4,434,000 after purchasing an additional 125,158 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of USANA Health Sciences by 64.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company’s stock valued at $4,582,000 after purchasing an additional 58,921 shares during the period. Vanguard Group Inc. grew its stake in USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after buying an additional 57,249 shares during the last quarter. Bank of America Corp DE grew its stake in USANA Health Sciences by 55.3% during the 3rd quarter. Bank of America Corp DE now owns 113,139 shares of the company’s stock worth $3,117,000 after buying an additional 40,274 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in USANA Health Sciences by 65.4% during the third quarter. Bridgeway Capital Management LLC now owns 87,455 shares of the company’s stock worth $2,409,000 after buying an additional 34,588 shares during the period. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.